期刊文献+

血清人附睾分泌蛋白4(HE4)对人卵巢癌诊断价值的Meta分析 被引量:9

Diagnostic Value of Serum Human Epididymis Protein 4 in Human Epithelial Ovarian Cancer:A Meta-analysis
暂未订购
导出
摘要 目的:通过Meta分析评价血清人附睾分泌蛋白4(HE4)对人卵巢癌的诊断价值。方法:系统检索Cochrane图书馆、Medline、Embase和中国生物医学文献数据库等数据库,选择以血清HE4诊断卵巢癌的临床诊断学试验。由两位评价者分别检索收集资料,用QUADAS评价文献质量,进行Meta分析,绘制综合受试者工作曲线(SROC)。主要是对SROC的曲线下面积(AUC)和诊断Q指数,其次是敏感性(Sen)、特异性(Sep)、诊断比值比(OR)进行分析。结果:共有26个诊断学试验纳入,对照组可分为良性盆腔病变和良性盆腔病变+健康为对照。良性盆腔病变为对照,整体诊断效率:AUC=0.888 2+0.015 0;Q指数0.818 8±0.0155。存在阈值效应引起的异质性。HE4的测量方法是引起阈值效应的原因。诊断早期(Ⅰ+Ⅱ期)卵巢癌:AUC=0.763 4+0.096 0;Q指数0.704 6+0.080 4。诊断绝经前卵巢癌:AUC=0.892 2+0.091 1;Q指数0.823 0+0.095 1。绝经后的卵巢癌:AUC=0.824 4±0.0371;Q指数0.757 5+0.033 5。在以良性盆腔病变+健康为对照的研究中,AUC=0.890 3+0.034 6;Q指数0.821 0+0.035 9,无阈值效应。人群是异质性的原因。诊断早期(Ⅰ+Ⅱ期)卵巢癌:AUC=0.883 4±0.046 0;Q指数0.814 0±0.046 9。结论:血清HE4对于卵巢癌的临床诊断均具有较高的曲线下面积和诊断Q指数,对卵巢癌诊断具有较高的临床价值。检测方法、民族地域是异质性的主要来源。 Objective: To quantitatively evaluate the diagnostic accuracy of the serum Epididymal Secretory Protein E4, for human epithelial ovarian cancer ( OEC ). Methods: A systematic search for relevant studies published between January 1997 and March 2011 was performed using the Medline, Embase, and China National Knowledge Infrastructure ( CNKI ) databases, among others. The criteria for inclusion were established based on the validity criteria for diagnostic research published by the Cochrane Methods Group on Screening and Diagnostic Test. Two reviewers independently assessed the methodological quality of each study by QUADAS ( Qual- ity Assessment of Diagnostic Accuracy Studies ). Statistical analysis was performed employing MATLAB Review Manager 4.2 and Meta-Disc 1.4. A meta-analysis of the reported sensitivity and specificity of each study and the Summary Receiver Operating Characteristic ( SROC ) curve was performed. Results: A total of 14 studies with benign control, and 14 with benign and healthy control were included. The area under the curve ( AUC ) of SROC was 0.8882 ± 0.0150, with Q index 0.8188 ± 0.0155 for benign control, and AUC was 0.8903 ± 0.0346 with Q index 0.8210 ± 0.0359 for benign and healthy control. Detection assay and population groups were the causes of heterogeneity by meta regression analysis. Conclusion: The assay method of race and country was the important source of heterogeneity. With the relative high AUC and Q index of HE4 antibody in patients with ovarian cancer, the positive HE4 antibody might be a useful parameter for the clinical diagnosis of patients with epithelial ovarian cancer.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2011年第24期1559-1564,共6页 Chinese Journal of Clinical Oncology
关键词 人附睾分泌蛋白4 卵巢癌 诊断试验 META分析 Human epididymal secretory protein E4 Ovarian cancer Diagnostic test Meta analysis
  • 相关文献

参考文献33

  • 1Andersen MR,Goff BA,Lowe KA,et al.Use of a Symptom Index,CA125,and HE4 to predict ovarian cancer[J].Gynecol Oncol,2010,116(3):378-383.
  • 2Drapkin R,von HHH,Lin Y,et al.Human epididymis protein 4 (HE4) is a secreted glycoprotcin that is overexpressed by serous and endometrioid ovarian carcinomas[J].Cancer Res,2005,65(6):2162-2169.
  • 3Hellstrom I,Raycraft J,Hayden-Ledbetter M,et al.The HE4 (WFDG2) protein is a biomarker for ovarian cardnoma[J].Cancer Res,2003,63(13):3695-3700.
  • 4Penny F Whiting,Marie E Weswood,Anne WS Rutjes,Johannes B Reitsma,Patrick NM Bossuyt,Jos Kleijnen,马章淳,钱楠.QUADAS评价:一种用于诊断性研究的质量评价工具(修订版)[J].中国循证医学杂志,2007,7(7):531-536. 被引量:65
  • 5张天嵩,钟文昭.Meta-DiSc软件在诊断试验Meta分析中的应用[J].循证医学,2008,8(2):97-100. 被引量:111
  • 6Van Gorp T,Gadron I,Despierre E,et al.HE4 and CA125 as a diagnostic test in ovarian cancer:prospective validation of the Risk of Ovarian Malignancy Algorithm[J].Br J Cancer,2011,104(5):863-870.
  • 7Jacob F,Meier M,Caduff R,et al.No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting[J].Gynecol Oncol,2011,121(3):487-491.
  • 8Shah CA,Lowe KA,Paley P,et al.Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers meso thelin,HE4,and CA125[J].Cancer Epidemiol Biomarkers Prev,2009,18(5):1365-1372.
  • 9Nolen B,Velikokhatnaya L,Marrangoni A,et al.Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass[J].Gynecol Oncol,2010,117(3):440-445.
  • 10Moore RG,Brown AK,Miller MC,et al.The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J].Gynecol Oncol,2008,108(2):402-408.

二级参考文献178

共引文献486

同被引文献71

  • 1Ya-Fei Zhu,Guo-Lan Gao,Sheng-Bo Tang,Zhen-Dong Zhang,Qing-Shui Huang.Effect of WFDC 2 silencing on the proliferation,motility and invasion of human serous ovarian cancer cells in vitro[J].Asian Pacific Journal of Tropical Medicine,2013,6(4):265-272. 被引量:12
  • 2章采奕,张淑芬,刘英姿,田焱,李新国,张瑜.eIF3a基因多态性与卵巢癌铂类药物治疗敏感性的关系[J].中南大学学报(医学版),2015,40(6):617-622. 被引量:3
  • 3高国兰,邹春芳,邹学森,陈文学.人卵巢上皮癌裸鼠皮下移植瘤模型的建立及生物学性状的鉴定[J].实用癌症杂志,2004,19(5):454-457. 被引量:9
  • 4Moore RG, Mc Meekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA 125 for the prediction of ovarian cancer in patients with a pelvic mass [ J ]. Gynecologic Oncology, 2009,112 (1) :40 -46.
  • 5Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary [ J ]. Controlled Clinical Trials, 1996,17 ( 1 ) : 1 - 12.
  • 6Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs the risk of malignancy Index for the predic- tion of epithelial ovarian cancer in patients with a pelvic mass[J]. Am Jobstet Gyneco1,2010,203 ( 3 ) :228. e1 - e6.
  • 7Jacob F, Meier M, Caduff R, et al. No benefit from combining HE4 and CA 125 as ovarian tumor markers in a clinical setting[ J]. Gynecol On- col,2011,121 (3) :487 -491.
  • 8Stiekema A, I_ok CAR, Kenter GG, et al. A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer[ J ]. Gynecol Onco1,2014,132 (3) :573 - 577.
  • 9Karlsen MA, Sandhu N, Hcgdall C, et al. Evaluation of HE4, CA 125, risk of ovarian malignancy algorithm(ROMA) and risk of malignancy index(RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass[J]. Gynecol Oncol,2012,127(2) :379 -383.
  • 10Bandiera E, Romani C, Specchia C, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management [ J ]. Cancer Epidem Biomar,2011,20 ( 12 ) :2496 - 2506.

引证文献9

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部